Consensus NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Market Closed - Nasdaq 04:00:00 2023-12-01 pm EST Intraday chart for NovoCure Limited 5-day change 1st Jan Change
12.50 USD +1.87% +0.24% -82.96%

Evolution of the average Target Price on NovoCure Limited

Price target over the last 5 years

History : Analyst Recommendations

2e01eab8e62365f2ef5620e2.d197-N6treckM-dfz1G-PQlVlGtzXizEj2RfP0h9wWY.AWwBkarbx7NLAr8yqWjRCX4yoR4rEWGvxQsIfDkpihE2ciLPt_ie0xwAkA~974db7981f05a63b2e72f99be89f2b53
Wedbush Adjusts NovoCure Price Target to $21 From $23, Maintains Neutral Rating MT
Wells Fargo Adjusts NovoCure's Price Target to $49 From $102, Keeps Overweight Rating MT
Wedbush Cuts NovoCure's Price Target to $23 From $46 After Drug Failure in Clinical Study, Maintains Neutral Rating MT
HC Wainwright Downgrades NovoCure to Neutral From Buy, Cuts Price Target to $25 From $85 MT
Piper Sandler Lowers Price Target on NovoCure to $35 From $45, Maintains Overweight Rating MT
Wedbush Cuts NovoCure's Price Target to $23 From $46, Maintains Neutral Rating MT
Piper Sandler Upgrades NovoCure to Overweight From Neutral, Price Target is $45 MT
SVB Securities Initiates NovoCure at Outperform With $51 Price Target MT
Evercore ISI Upgrades NovoCure to In Line From Underperform, Price Target is $33 MT
Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53 MT
Piper Sandler Adjusts Price Target on NovoCure to $62 From $67, Maintains Neutral Rating MT
Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53 MT
Wells Fargo Upgrades NovoCure to Overweight From Equalweight, Adjusts Price Target to $104 From $70 MT
Wedbush Cuts NovoCure's Price Target to $53 From $65 After Lower-Than-Expected Q1 Results, Keeps Underperform Rating MT
JPMorgan Downgrades NovoCure to Underweight From Neutral, Adjusts Price Target to $50 From $99 MT
Piper Sandler Adjusts NovoCure's Price Target to $80 From $70, Maintains Neutral Rating MT
JPMorgan Adjusts NovoCure's Price Target to $99 From $86, Keeps Neutral Rating MT
Wells Fargo Downgrades NovoCure to Equalweight From Overweight, Adjusts Price Target to $107 From $89 MT
HC Wainwright Adjusts NovoCure's Price Target to $140 From $100, Maintains Buy Rating MT
Wells Fargo Upgrades NovoCure to Overweight From Equalweight, Adjusts Price Target to $89 From $74 MT
Wells Fargo Adjusts Price Target on NovoCure to $74 From $70, Keeps Equal Weight Rating MT
Truist Securities Trims NovoCure's Price Target to $102 From $105, Maintains Buy Rating MT
HC Wainwright Adjusts NovoCure's Price Target to 100 From $115, Keeps Buy Rating MT
Wedbush Lowers NovoCure's Price Target to $43 From $45, Keeps Underperform Rating MT
Piper Sandler Downgrades NovoCure to Neutral From Overweight, Adjusts Price Target to $70 From $90 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
12.50USD
Average target price
26.14USD
Spread / Average Target
+109.14%
High Price Target
49.00USD
Spread / Highest target
+292.00%
Low Price Target
15.00USD
Spread / Lowest Target
+20.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NovoCure Limited

Wedbush
Wells Fargo Securities
HC Wainwright
Piper Sandler
SVB Securities LLC
Evercore ISI
JPMorgan Chase
Truist Securities
Loop Capital
Oppenheimer
Mizuho Securities
Northland Securities
J.P. Morgan Chase
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
More Ratings
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer